肺癌预后评估:轴位、多平面与三维CT测量与病理大小的比较
该回顾性研究纳入544例无病理淋巴结转移的肺癌手术患者,比较基于轴位、多平面和三维CT测量的临床T分期与病理T分期的预后性能。多平面测量与病理分期一致性最高(67.5%),但各测量方法基于大小的分期预后性能无显著差异。
要点
- 多平面CT测量与病理T分期一致性最高,优于轴位和三维测量。
- 基于轴位、多平面、三维CT测量的临床T分期预后性能与病理T分期无显著差异。
- 日常阅片可采用多平面测量进行临床T分期,以提高与病理分期的一致性。
核心结论
- 基于不同大小测量方法的肿瘤分期预后性能无显著差异。
- 多平面测量与病理分期一致性最高,可能更适合用于临床分期。
研究设计与样本
- 基于轴位、多平面(轴位、冠状位、矢状位)图像及三维肿瘤mask上的最大肿瘤大小确定临床T分期。
- 采用一致性指数(C-index)比较临床与病理T分期对无病生存(DFS)的预后性能。
诊断标准与关键数值
- 轴位、多平面、三维肿瘤mask及病理的平均肿瘤大小分别为30.8±17.3、33.9±19.4、39.2±21.4、33.4±18.0 mm。
临床应用与阅片要点
- 临床T分期可优先采用多平面测量,以提高与病理分期的一致性。
- 基于CT大小测量的临床T分期预后性能与病理T分期相当,可用于预后评估。
局限性
- 回顾性研究设计。
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to compare the prognostic performance of clinical T staging based on axial, multiplanar, and 3-dimensional measurement on CT with that of pathological T staging in patients with non-small cell lung cancer.
METHOD: Patients with surgically resected lung cancer without pathological node metastasis between June 2010 and December 2017 were retrospectively included. Clinical T stages were determined based on the maximal tumor size on axial, multiplanar (axial, coronal, and sagittal) images and 3-dimensional tumor mask. The prognostic performances of clinical and pathological T staging for disease-free survival (DFS) were compared using the concordance indices (C-indices).
RESULTS: A total of 544 patients (64.7 ± 9.7 years, 352 men) were included; 160 patients (29.4%) experienced events including 29 (5.3%) who expired. The median DFS was 44.1 months. The mean tumor size on axial, multiplanar images, 3-dimensional tumor mask, and pathology was 30.8 ± 17.3, 33.9 ± 19.4, 39.2 ± 21.4, and 33.4 ± 18.0 mm, respectively. Clinical staging based on multiplanar measurement showed a higher agreement (67.5% [367/544]) with pathological staging than axial (60.5% [329/544]) and 3-dimensional measurement (50.9% [277/544]) based staging did (p = .0005 and <.0001, respectively). The adjusted C-indices of axial, multiplanar, 3-dimensional, and pathological tumor stages were 0.66 (95% confidence interval [CI]: 0.66-0.67), 0.66 (95% CI: 0.66-0.66), 0.67 (95% CI: 0.67-0.67), and 0.67 (95% CI: 0.66-0.67), respectively (p > .05).
CONCLUSIONS: The prognostic performances of tumor staging according to size measurement methods were not significantly different. Multiplanar measurement may be preferable for clinical staging considering its highest agreement with pathological staging.
引用
- Jeong B, Lee SM, Park S, et al. Prognostic performance in lung cancer according to tumor size: Comparison of axial, multiplanar, and 3-dimensional CT measurement to pathological size. Eur J Radiol. 2021. PMID: 34695694. doi:10.1016/j.ejrad.2021.109976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。